Hcw Biologics Stock EBITDA
| HCWB Stock | USD 4.13 0.11 2.59% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess HCW Biologics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| EBITDA | -27.7 M | -26.3 M |
HCW | EBITDA | Build AI portfolio with HCW Stock |
HCW Biologics Company EBITDA Analysis
HCW Biologics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current HCW Biologics EBITDA | (27.68 M) |
Most of HCW Biologics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HCW Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
HCW EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for HCW Biologics is extremely important. It helps to project a fair market value of HCW Stock properly, considering its historical fundamentals such as EBITDA. Since HCW Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HCW Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HCW Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
HCW Ebitda
Ebitda |
|
According to the company disclosure, HCW Biologics reported earnings before interest,tax, depreciation and amortization of (27.68 Million). This is 103.15% lower than that of the Biotechnology sector and 127.64% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.71% higher than that of the company.
HCW EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HCW Biologics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HCW Biologics could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics of similar companies.HCW Biologics is currently under evaluation in ebitda category among its peers.
HCW Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, HCW Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to HCW Biologics' managers, analysts, and investors.Environmental | Governance | Social |
HCW Biologics Institutional Holders
Institutional Holdings refers to the ownership stake in HCW Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of HCW Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing HCW Biologics' value.| Shares | Advisor Group Holdings, Inc. | 2025-03-31 | 1 K | Bank Of America Corp | 2025-03-31 | 210 | Tower Research Capital Llc | 2025-03-31 | 32.0 | Hightower Advisors, Llc | 2025-03-31 | 0.0 | Bridgeway Capital Management, Llc | 2025-03-31 | 0.0 | Renaissance Technologies Corp | 2025-03-31 | 0.0 | Armistice Capital, Llc | 2025-03-31 | 0.0 | Two Sigma Investments Llc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-03-31 | 0.0 | Honkamp Krueger Financial Services Inc | 2025-03-31 | 279.5 K | Vanguard Group Inc | 2025-03-31 | 243.2 K |
HCW Fundamentals
| Return On Equity | -277.26 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (782.98) % | ||||
| Current Valuation | 23.3 M | ||||
| Shares Outstanding | 2.54 M | ||||
| Shares Owned By Insiders | 29.80 % | ||||
| Shares Owned By Institutions | 1.35 % | ||||
| Number Of Shares Shorted | 51.88 K | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 7.25 X | ||||
| Revenue | 2.57 M | ||||
| Gross Profit | 345.67 K | ||||
| EBITDA | (27.68 M) | ||||
| Net Income | (30.02 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 13.69 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (7.62) X | ||||
| Cash Flow From Operations | (14.23 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (24.80) X | ||||
| Target Price | 35.0 | ||||
| Number Of Employees | 36 | ||||
| Beta | 0.65 | ||||
| Market Capitalization | 10.47 M | ||||
| Total Asset | 30.24 M | ||||
| Retained Earnings | (100.56 M) | ||||
| Working Capital | (23.93 M) | ||||
| Net Asset | 30.24 M |
About HCW Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HCW Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCW Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCW Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out HCW Biologics Piotroski F Score and HCW Biologics Altman Z Score analysis. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (24.80) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.